InVitae Corp (NVTA):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8261)
◆英語タイトル:InVitae Corp (NVTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8261
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:53
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Invitae Corp (Invitae), formerly Locus Development Inc, is a genetic information company which processes DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. The company’s portfolio of diagnostic tests includes preimplantation and carrier screening for inherited disorders, miscarriage analysis, neurological disorders, metabolic disorders and pediatric and developmental disorders among others. Invitae specializes in offering exome analysis, panel and single gene genetic tests. It also provides proactive testing, genetic counseling resources, re-requistion testing, family variant testing and VUS resolution testing and clinical consult services. Invitae is headquartered in San Francisco, California, the US.

InVitae Corp (NVTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
InVitae Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
InVitae Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
InVitae Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
InVitae Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
InVitae Corp, Medical Devices Deals, 2012 to YTD 2018 10
InVitae Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
InVitae Corp, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
InVitae Raises USD16 Million in Venture Financing 12
InVitae Raises US$29.6 Million In Venture Financing 13
Partnerships 14
InVitae Expands Partnership with Sarepta Therapeutics 14
Invitae Enters into Agreement with Alnylam Pharma 15
Good Start Genetics Enters into Agreement with IviGen and iGenomix 16
Licensing Agreements 17
Good Start Genetics Enters into Licensing Agreement with Johns Hopkins University 17
Good Start Genetics Expands Licensing Agreement with Johns Hopkins University 18
Equity Offering 19
Invitae Prices Public Offering of Shares for USD50 Million 19
Invitae to Raise Funds through Public Offering of Shares 21
Invitae to Raise Funds through Public Offering of Shares 22
Invitae Raises USD73.5 Million in Private Placement of Shares and Preferred Shares 23
CombiMatrix Raises USD8 Million in Public Offering of Units 24
CombiMatrix Raises USD3.34 Million in Private Placement of Warrants 26
CombiMatrix Raise USD5 Million in Private Placement of Securities 28
CombiMatrix Completes Public Offering Of Units For US$12 Million 30
CombiMatrix Completes Second Tranche Of Private Placement Of Preferred Shares For US$1.2 Million 31
CombiMatrix Completes Private Placement Of Common Stock For US$0.4 Million 32
CombiMatrix Completes Private Placement Of Units For US$1.6 Million 33
Asset Transactions 34
Molecular Loop Acquires MIP-Based DNA Targeting Technology from Invitae 34
Acquisition 35
Invitae Acquires CombiMatrix for USD35 Million 35
InVitae Corp – Key Competitors 37
InVitae Corp – Key Employees 38
InVitae Corp – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Aug 07, 2018: Invitae reports more than 160% annual revenue growth driven by nearly 140% annual growth in volume in second quarter 2018 40
May 09, 2018: Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018 41
Feb 12, 2018: Invitae reports over 150% volume and over 170% revenue growth for 2017 43
Jan 08, 2018: Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018 45
Nov 06, 2017: Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017 46
Aug 07, 2017: Invitae Reports Second Quarter 2017 Results 49
Corporate Communications 51
Sep 11, 2018: Invitae names Chitra Nayak to its Board of Directors 51
Product News 52
Dec 05, 2017: Invitae to present findings at 2017 San Antonio Breast Cancer Symposium 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
InVitae Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
InVitae Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
InVitae Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
InVitae Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
InVitae Corp, Deals By Therapy Area, 2012 to YTD 2018 9
InVitae Corp, Medical Devices Deals, 2012 to YTD 2018 10
InVitae Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
InVitae Raises USD16 Million in Venture Financing 12
InVitae Raises US$29.6 Million In Venture Financing 13
InVitae Expands Partnership with Sarepta Therapeutics 14
Invitae Enters into Agreement with Alnylam Pharma 15
Good Start Genetics Enters into Agreement with IviGen and iGenomix 16
Good Start Genetics Enters into Licensing Agreement with Johns Hopkins University 17
Good Start Genetics Expands Licensing Agreement with Johns Hopkins University 18
Invitae Prices Public Offering of Shares for USD50 Million 19
Invitae to Raise Funds through Public Offering of Shares 21
Invitae to Raise Funds through Public Offering of Shares 22
Invitae Raises USD73.5 Million in Private Placement of Shares and Preferred Shares 23
CombiMatrix Raises USD8 Million in Public Offering of Units 24
CombiMatrix Raises USD3.34 Million in Private Placement of Warrants 26
CombiMatrix Raise USD5 Million in Private Placement of Securities 28
CombiMatrix Completes Public Offering Of Units For US$12 Million 30
CombiMatrix Completes Second Tranche Of Private Placement Of Preferred Shares For US$1.2 Million 31
CombiMatrix Completes Private Placement Of Common Stock For US$0.4 Million 32
CombiMatrix Completes Private Placement Of Units For US$1.6 Million 33
Molecular Loop Acquires MIP-Based DNA Targeting Technology from Invitae 34
Invitae Acquires CombiMatrix for USD35 Million 35
InVitae Corp, Key Competitors 37
InVitae Corp, Key Employees 38
InVitae Corp, Subsidiaries 39

List of Figures
InVitae Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
InVitae Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
InVitae Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
InVitae Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
InVitae Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
InVitae Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
InVitae Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
InVitae Corp, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ InVitae Corp (NVTA):製薬・医療:M&Aディール及び事業提携情報(InVitae Corp (NVTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆